drugset / Trial / NCT02093468

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468 ↗

Phase 2 Terminated 4 enrolled Mast Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of MST-188 in subjects receiving catheter-directed rt-PA for acute lower limb ischemia and to evaluate whether treatment with MST-188 results in more rapid thrombolysis of the occlusion and more rapid tissue perfusion in the effected blood vessel.

Timeline

Start
2014-06
Primary completion
2016-12
Completion
—

Outcome

Outcome not reported

Stopped: “Program discontinued to persue alternate indications.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vepoloxamer Small molecule 25 mg/kg Intravenous
Subject Vepoloxamer Small molecule 75 mg/kg Intravenous

Indications